Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · Real-Time Price · USD
63.61
+0.16 (0.25%)
Dec 12, 2024, 9:43 AM EST - Market open
0.25%
Market Cap 3.34B
Revenue (ttm) 13.05M
Net Income (ttm) -60.54M
Shares Out 52.48M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 36,352
Open 64.00
Previous Close 63.45
Day's Range 62.14 - 64.00
52-Week Range 7.79 - 71.71
Beta 3.29
Analysts Strong Buy
Price Target 83.09 (+30.62%)
Earnings Date Nov 6, 2024

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2021
Employees 64
Stock Exchange NASDAQ
Ticker Symbol JANX
Full Company Profile

Financial Performance

In 2023, Janux Therapeutics's revenue was $8.08 million, a decrease of -6.14% compared to the previous year's $8.61 million. Losses were -$58.29 million, -7.56% less than in 2022.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is $83.09, which is an increase of 30.62% from the latest price.

Price Target
$83.09
(30.62% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...

5 days ago - Business Wire

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...

7 days ago - Business Wire

Janux Therapeutics Announces Proposed Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering.

8 days ago - Business Wire

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

On Monday, Janux Therapeutics, Inc.  JANX revealed updated interim clinical data for its JANX007 clinical program.

8 days ago - Benzinga

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

The therapeutics company reports encouraging Phase 1 trial results for a novel cancer treatment.

8 days ago - Barrons

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC.

9 days ago - Business Wire

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA ...

23 days ago - Seeking Alpha

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release.

5 weeks ago - Business Wire

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights.

4 months ago - Business Wire

Janux Therapeutics Announces Updates to Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...

5 months ago - Business Wire

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer ...

6 months ago - Seeking Alpha

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights.

7 months ago - Business Wire

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above t...

8 months ago - Invezz

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatme...

8 months ago - Seeking Alpha

VKTX, JANX and these biotech stocks are surging in 2024

Forget artificial intelligence stocks like Nvidia and Super Micro Computer. Biotech stocks are doing much better this year.

9 months ago - Invezz

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc  JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.

9 months ago - Benzinga

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights.

9 months ago - Business Wire

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants.

10 months ago - Business Wire

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. Wi...

10 months ago - Seeking Alpha

Janux Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering of Common Stock.

10 months ago - Business Wire

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Janux Therapeutics shares more than doubled in value before the bell on Tuesday after the drug developer reported encouraging interim early-stage data for its experimental therapy to treat an advanced...

10 months ago - Reuters

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors.

10 months ago - Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008.

10 months ago - Business Wire

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer.

1 year ago - Business Wire